ATLANTA, Dec. 22, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the pricing of its initial public...
from PR Newswire: https://ift.tt/2JemHRR
No comments:
Post a Comment